Apolipoprotein E promoter polymorphisms (−491A/T and −427T/C) and Alzheimer’s disease: no evidence of association in the Irish population
- 91 Downloads
Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder with as yet poorly understood aetiology. Both environmental and genetic factors have been implicated as predisposing factors. The APOE e4 allele is an established genetic susceptibility factor for AD for several populations including the Irish. Polymorphisms (−491A/T and −427T/C) at the promoter region of the APOE gene are postulated to affect the expression of the gene through differential binding of transcription factors.
Two APOE promoter polymorphisms (−491A/T and −427T/C) are examined for possible association with AD.
Using a case-control study design, a sample of 112 Irish late onset Alzheimer’s (LOAD) patients and 107 ethnically matched controls were investigated for association with the above polymorphisms.
No evidence of association between any of the examined markers and AD was observed. Haplotype analysis using markers −491A/T and −427T/C in conjunction with the APOE (Hha I) polymorphism revealed significant associations of three haplotypes with AD. However, this association was mainly due to the highly significant association of the APOE e4 allele with AD and not of the promoter variants.
KeywordsAlzheimer’s disease Apolipoprotein E Promoter polymorphisms
We would like to acknowledge the Mercer Foundation, the Medical Research Council (UK), the Health Research Board and the Higher Education Authority for financial support.
- 12.Bennett C, Crawford F, Osborne A, Diaz P, Hoyne J, Lopez R, Roq Duara R, Rossor M, Mullan M (1995) Evidence that the APOE locus influences rate of disease progression in late onset familial Alzheimer’s disease but is not causative. Am J Hum Genet 60(1):1–6Google Scholar
- 15.Roks G, Houwing-Duistermaat JJ, Dermaut B, Serneels S, Havekes LM, Hofman A, Breteler MMB, Van Broeckhoven C, Van Duijn CM (2002) Effect of the APOE −491A/T promoter polymorphism on apolipoprotein E levels and risk of Alzheimer’s disease: the Rotterdam Study. Am J Med Genet 114:570–573PubMedCrossRefGoogle Scholar
- 16.Zurutuza L, Verpillat P, Raux G, Hannequin D, Puel M, Belliard S, Michon A, Pothin Y, Camuzat A, Penet C, Martin C, Brice A, Campion D, Clerget-Darpoux F, Frebourg T (2000) APOE promoter polymorphisms do not confer independent risk for Alzheimer’s disease in a French population. Eur J Hum Genet 8(9):713–716PubMedCrossRefGoogle Scholar
- 18.Lambert JC, Berr C, Pasquier F, Delacourte A, Frigard B, Cottel D, Perez-Tur J, Mouroux V, Mohr M, Cecyre D, Galasko D, Lendon C, Poirier J, Hardy J, Mann D, Amouyel P, Chartier-Harlin MC (1998) Pronounced impact of Th1/E47cs mutation compared with −491 AT mutation on neural APOE gene expression and risk of developing Alzheimer’s disease. Hum Mol Genet 7(9):1511–1516PubMedCrossRefGoogle Scholar
- 20.Johnson GC, Esposito L, Barratt BJ, Smith AN, Heward J, Di Genova G, Ueda H, Cordell HJ, Eaves IA, Dudbridge F, Twells RC, Payne F, Hughes W, Nutland S, Stevens H, Carr P, Tuomilehto-Wolf E, Tuomilehto J, Gough SC, Clayton DG, Todd JA (2001) Haplotype tagging for the identification of common disease genes. Nat Genet 29(2):233–237PubMedCrossRefGoogle Scholar
- 21.Town T, Paris D, Fallin D, Duara R, Barker W, Gold M, Crawford F, Mullan M (1998) The −491 A/T apolipoprotein E promoter polymorphism association with Alzheimer’s disease: independent risk and linkage disequilibrium with the known APOE polymorphism. Neurosci Lett 252:95–98PubMedCrossRefGoogle Scholar